Clinical Trials for Osteoarthritis

492 osteoarthritis trials indexed, 181 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Osteoarthritis

Osteoarthritis is a common joint condition that causes the breakdown of cartilage, the smooth tissue that cushions the ends of bones. This wear and tear lead to bones rubbing against each other, which results in pain, swelling, and reduced movement. The underlying biology involves changes in the cartilage, bone, and surrounding tissues, including inflammation and the formation of bone spurs. Doctors diagnose osteoarthritis through a combination of medical history, physical exams, and imaging tests such as X-rays or MRI scans. These tests help show joint space narrowing, cartilage loss, and other structural changes.

Symptoms of osteoarthritis often include joint pain, stiffness, swelling, and a decreased range of motion. These symptoms usually develop gradually and worsen over time. The condition most commonly affects people over the age of 50, although it can occur earlier, especially in those with joint injuries or genetic predispositions. Women are more likely to develop osteoarthritis than men, particularly after menopause. Other risk factors include obesity, repetitive joint use, previous joint trauma, and certain metabolic diseases.

Osteoarthritis is a significant medical and social issue worldwide. It is the most common form of arthritis and affects approximately 32.5 million adults in the United States alone. The condition is a leading cause of disability, limiting daily activities and work capacity. Economically, osteoarthritis contributes to billions of dollars in healthcare costs and lost productivity each year. Its high prevalence and impact on quality of life make it a priority for ongoing research and treatment development.

The Osteoarthritis Treatment Landscape

The first-line treatment for osteoarthritis typically focuses on non-drug approaches and symptom management. Patients are encouraged to maintain a healthy weight, engage in low-impact exercise, and use physical therapy to strengthen muscles around affected joints. Over-the-counter pain relievers such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended to reduce pain and inflammation. These initial steps aim to improve joint function and delay the need for more invasive treatments.

If symptoms persist or worsen, second-line treatments may include stronger pain medications or prescription NSAIDs. In some cases, doctors may recommend corticosteroid injections directly into the joint to reduce inflammation temporarily. Third-line options involve advanced interventions such as hyaluronic acid injections, which aim to lubricate the joint, or surgery, including joint replacement for severe cases. The choice of treatment depends on symptom severity, joint affected, and patient health status.

Despite these options, many patients continue to experience pain and disability. Some subgroups respond poorly to existing treatments or develop side effects from long-term medication use, such as gastrointestinal issues from NSAIDs. There is also a lack of therapies that can slow or reverse cartilage damage. Research efforts focus on closing these gaps by exploring new drug classes, biologics, and regenerative medicine approaches. Clinical trials play a key role in testing these potential improvements.

Why Clinical Trials Matter for Osteoarthritis

Clinical trials offer patients the chance to access new therapies that are not yet widely available. They also provide closer monitoring by healthcare professionals and the opportunity to contribute to scientific knowledge that may benefit others in the future. Currently, there are 492 osteoarthritis clinical trials indexed on ClinicalTrials.gov, with 181 actively recruiting participants. This number reflects ongoing efforts to find better treatments and improve the understanding of the disease.

Participating in a clinical trial involves some risks and considerations. The effectiveness of the experimental treatment is not guaranteed, and some participants may receive a placebo instead of the active drug. Trials often require additional clinic visits and tests, which can be time-consuming. Side effects may occur, and their severity can vary depending on the treatment being studied. Patients should weigh these factors carefully and discuss them with their healthcare providers before enrolling.

The landscape of osteoarthritis clinical trials includes sponsors from academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in advancing knowledge and developing new therapies. ClinicalTrials.gov serves as a central registry to provide transparency and public access to information about ongoing and completed trials. This registry helps patients, caregivers, and healthcare professionals find relevant studies and understand the current research environment.

What to Look for in a Osteoarthritis Clinical Trial

Clinical trials are divided into four main phases, each serving a different purpose. Phase 1 trials test the safety of a new treatment in a small group of people. Phase 2 trials focus on how well the treatment works and continue to assess safety. Phase 3 trials involve larger groups to confirm effectiveness and monitor side effects. Phase 4 trials happen after a treatment is approved to gather more information on its long-term effects. For osteoarthritis, the majority of trials are not assigned a specific phase (NA: 221). Among those with phases, Phase 2 trials are the most common (54), followed by Phase 1 (35) and Phase 3 (30).

When joining an osteoarthritis clinical trial, you will often see specific inclusion criteria. These criteria help ensure that the study results apply to a particular group of patients. Common requirements include age limits, often adults over 40 or 50 years old. Prior treatments may be considered, such as whether you have used certain medications or therapies before. Some trials look for specific biomarkers or signs in blood tests or imaging studies. The stage of osteoarthritis and how long you have had the disease are also important factors. These help researchers understand how the treatment works at different points in the disease.

Exclusion criteria are equally important. They protect participants by preventing those with certain risks from joining. For osteoarthritis trials, common exclusions include having other serious health conditions like heart disease or uncontrolled diabetes. Some medications might interfere with the study drug, so patients taking those are often excluded. Safety thresholds, such as limits on kidney or liver function, are also used to keep participants safe. These rules help ensure the trial can measure the treatment effects without other factors causing problems.

Practical considerations matter a lot when deciding to join a trial. The length of the study can range from a few weeks to several months or more. You will need to attend scheduled visits for tests, treatments, and check-ups. Some trials require travel to a study site, which can be a challenge depending on your location. Before joining, ask the research team important questions: How long will the trial last? How often will I need to visit the site? What are the possible side effects? And what happens if I decide to leave the trial early? Understanding these details can help you decide if the trial fits your needs and lifestyle.

Primary Sources and Further Reading

For those interested in learning more about osteoarthritis and clinical trials, it is important to use reliable sources. These websites offer trustworthy information on osteoarthritis symptoms, treatments, and ongoing research. They also provide guidance on how to participate in clinical trials safely and effectively.

Latest Research and Emerging Treatments for Osteoarthritis (2026)

Osteoarthritis treatment is evolving with several Phase 3 trials testing new drugs that may help reduce pain and improve function. Novo Nordisk is studying NNC0487-0111, an injectable medicine given once a week, designed for adults with excess body weight and knee osteoarthritis (NCT07481630, NCT07509307). This drug aims to help patients lose weight while also reducing knee pain. Early data suggests that by lowering body weight, the stress on knee joints may decrease, potentially easing symptoms and improving daily mobility.

Other research focuses on drugs that target both obesity and joint pain. Eli Lilly is conducting trials on Eloralintide and Orforglipron (NCT07353931, NCT07153471), two once-weekly treatments for people who are overweight or obese with knee osteoarthritis. These drugs belong to a class that may help regulate appetite and metabolism, which could support weight loss and reduce inflammation in the joints. If these treatments prove safe and effective, they could offer a dual approach to managing osteoarthritis symptoms and weight-related factors.

Another promising study is testing SL1002, a single-dose injectable drug aimed at relieving knee pain caused by osteoarthritis (NCT07226258). This treatment is designed to provide pain relief with just one injection, which could simplify management for patients who experience frequent discomfort. These ongoing trials reflect the growing focus in osteoarthritis research on addressing both pain and factors like weight that affect joint health. New drugs for osteoarthritis in 2026 may offer more personalized options to improve quality of life for many patients.

Frequently asked questions about Osteoarthritis trials

How do I find Osteoarthritis clinical trials?

The authoritative source for Osteoarthritis clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 492 osteoarthritis studies are currently indexed. You can search by entering "osteoarthritis" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new osteoarthritis trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Osteoarthritis trials in?

Across the 492 osteoarthritis trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Osteoarthritis clinical trials are currently recruiting?

As of the latest scan, 181 osteoarthritis trials have a "Recruiting" status on ClinicalTrials.gov, out of 492 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting osteoarthritis trial matches their tracked condition.

Stay informed about osteoarthritis research

Get a weekly briefing with the trials that matter most.

Start monitoring osteoarthritis trials